¿Cuál es la fisiopatología de la dislipidemia mixta?

Respuesta generada por Itaca · 13 fuentes · 18 de mayo de 2026

Pregunta original

Explica la fisiopatología de la dislipidemia mixta

Summary
Mixed dyslipidemia is characterized by the coexistence of elevated triglycerides, low HDL‑cholesterol, and often increased small dense LDL particles. The central mechanism is overproduction and/or reduced clearance of triglyceride‑rich lipoproteins, usually on a background of insulin resistance and excess free fatty acid flux from adipose tissue to the liver. This promotes exchange of triglycerides and cholesteryl esters between lipoproteins, generating triglyceride‑rich, HDL‑ and LDL‑particles that are rapidly catabolized (↓HDL) or become small and dense (atherogenic LDL). Genetic variants, obesity, type 2 diabetes, metabolic syndrome, and lifestyle factors modulate this pathophysiologic core.[1]``[2]


1. Definition and main lipid abnormalities

Mixed (combined) dyslipidemia typically includes:

  1. Elevated fasting triglycerides (often 150–500 mg/dL; can be higher).
  2. Low HDL‑cholesterol.
  3. Elevated non‑HDL‑cholesterol and apoB, frequently with:
    • Normal or mildly elevated LDL‑C by standard calculation
    • But increased number of LDL particles, predominantly small dense LDL.[1]``[2]

This pattern is common in insulin resistance, metabolic syndrome, and type 2 diabetes.[1]``[3]


2. Central role of insulin resistance and free fatty acid flux

2.1 Adipose tissue dysfunction

In obesity and insulin resistance, adipocytes show:

  • Reduced antilipolytic response to insulin → increased lipolysis.
  • Increased release of free fatty acids (FFA) to the portal circulation.[3]``[4]

Consequences:

  • Excess FFA uptake by the liver.
  • Increased hepatic triglyceride synthesis and steatosis (NAFLD).
  • Substrate oversupply for VLDL production.[3]``[4]

2.2 Hepatic overproduction of VLDL

The liver responds to increased FFA and hepatic triglyceride content by:

  • Increasing synthesis of apoB100.
  • Increasing assembly and secretion of large, triglyceride‑rich VLDL1 particles.[3]``[5]

This overproduction of VLDL is a hallmark of mixed dyslipidemia in insulin‑resistant states.[5]


3. Impaired clearance of triglyceride‑rich lipoproteins

3.1 Lipoprotein lipase (LPL) dysfunction

In insulin resistance:

  • LPL expression and activity in peripheral tissues (especially adipose) is reduced.
  • Muscle and adipose tissue take up less triglyceride from circulating VLDL and chylomicrons.[4]``[6]

Result:

  • Delayed catabolism of VLDL and chylomicrons.
  • Accumulation of triglyceride‑rich particles and remnants (elevated triglycerides; remnant lipoproteins).

Inflammation and adipokine imbalance (↓adiponectin, ↑TNF‑α, ↑IL‑6) further impair LPL and lipid metabolism.[3]``[4]

3.2 Remnant lipoproteins

Incomplete lipolysis yields cholesterol‑rich remnants (VLDL remnants, IDL, chylomicron remnants) that:

  • Are highly atherogenic.
  • Can penetrate the arterial wall and be taken up by macrophages without prior oxidation.[2]``[7]

This contributes significantly to ASCVD risk beyond LDL‑C in mixed dyslipidemia.[2]``[7]


4. CETP‑mediated exchange and generation of atherogenic LDL and HDL

Cholesteryl ester transfer protein (CETP) catalyzes exchange of:

  • Triglycerides from VLDL ↔ cholesteryl esters from HDL and LDL.[2]``[5]

In hypertriglyceridemia (high VLDL pool):

  1. HDL and LDL become enriched in triglycerides and relatively depleted of cholesteryl ester.
  2. Hepatic lipase preferentially hydrolyzes triglyceride‑rich HDL and LDL →
    • HDL becomes smaller and is cleared faster via the kidney and liver → ↓HDL‑C and ↓apoA-I.
    • LDL particles shrink and become small dense LDL (sdLDL).[2]``[5]``[8]

Small dense LDL properties:

  • Greater arterial wall penetration.
  • Higher susceptibility to oxidation and glycation.
  • Lower affinity for LDL receptor → prolonged plasma residence time.[2]``[8]

This “atherogenic lipoprotein phenotype” (↑TG, ↓HDL‑C, ↑sdLDL) is characteristic of mixed dyslipidemia related to insulin resistance.[2]``[8]


5. ApoB and particle number vs cholesterol content

In many patients with mixed dyslipidemia:

  • Measured LDL‑C may be normal or only mildly elevated.
  • But apoB and total atherogenic particle number (LDL + VLDL remnants) are clearly increased.[1]``[2]

Reasons:

  • A high number of cholesterol‑poor, triglyceride‑rich particles (VLDL remnants, sdLDL).
  • Cholesterol mass per particle is reduced, so LDL‑C underestimates atherogenic burden.

Hence guidelines emphasize non‑HDL‑C and apoB as better risk markers in mixed dyslipidemia.[1]``[9]


6. Genetic and primary forms

While most mixed dyslipidemia is secondary to insulin resistance, obesity, or diabetes, there are “primary” or familial forms:

  1. Familial combined hyperlipidemia (FCHL)

    • Polygenic; characterized by overproduction of apoB‑containing lipoproteins.
    • Variable phenotype within families: high LDL‑C, high TG, or both; consistently high apoB.
    • Often associated with increased VLDL1 production, sdLDL, and low HDL‑C.[10]
  2. Other genetic contributors

    • Variants in LPL, APOA5, APOC3, ANGPTL3/4, and GPIHBP1 that impair triglyceride‑rich lipoprotein metabolism can deepen the mixed pattern in the presence of secondary factors.[6]``[11]

These genetic backgrounds interact with lifestyle and metabolic factors to express the mixed phenotype.


7. Role of hyperglycemia and diabetes‑specific mechanisms

In type 2 diabetes and poorly controlled glycemia:

  • Glycation of apolipoproteins (apoB, apoA‑I) alters receptor interactions and catabolism.
  • Glycated LDL is more susceptible to oxidation and less readily cleared.
  • Hepatic lipase activity may be increased, promoting formation of sdLDL and HDL catabolism.[3]``[12]

Thus diabetes amplifies the atherogenic consequences of the mixed dyslipidemia pattern.


8. Organ‑level and vascular consequences

8.1 Liver (NAFLD → NASH)

  • Excess FFA flux and increased VLDL synthesis promote hepatic steatosis.
  • NAFLD further worsens hepatic insulin resistance and VLDL overproduction, forming a vicious circle.[4]``[13]

8.2 Arterial wall

  • Accumulation of remnant lipoproteins, sdLDL, and modified LDL in the subendothelial space → foam cell formation.
  • Endothelial dysfunction via oxidative stress, inflammatory cytokines, and reduced nitric oxide bioavailability.
  • Promotion of plaque progression and vulnerability.[2]``[7]``[8]

Mixed dyslipidemia, especially when coupled with metabolic syndrome or diabetes, markedly increases ASCVD risk; this underpins guideline recommendations for intensive risk factor control (statins as first‑line, plus lifestyle, ± additional agents depending on TG and risk).[1]``[9]


9. Key pathophysiologic steps (integrated view)

  1. Insulin resistance / adipose dysfunction → increased lipolysis and FFA flux.
  2. Liver: FFA overload → ↑TG synthesis, ↑VLDL (especially VLDL1) secretion.
  3. Reduced LPL activity → delayed clearance of VLDL/chylomicrons → hypertriglyceridemia and remnant accumulation.
  4. CETP‑mediated lipid exchange → triglyceride‑rich HDL and LDL.
  5. Hepatic lipase action → rapid HDL catabolism (↓HDL‑C) and generation of sdLDL.
  6. Net effect: ↑TG, ↓HDL‑C, normal/slightly ↑LDL‑C but ↑apoB and atherogenic particle number (sdLDL and remnants).
  7. Clinical consequence: high atherogenicity and association with metabolic syndrome, type 2 diabetes, and NAFLD.

If you tell me the clinical context you’re interested in (e.g., “mixed dyslipidemia in a patient with T2D and NAFLD” or “familial combined hyperlipidemia”), I can tailor the explanation to that phenotype and link it more directly to specific management strategies.


[1] 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. [1]
[2] Chapman MJ et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease. Eur Heart J. [2]
[3] Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. [3]
[4] Engin A. Adipose tissue and lipotoxicity. Adv Exp Med Biol. [4]
[5] Adiels M et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. [5]
[6] Dron JS, Hegele RA. Genetics of triglycerides and the risk of atherosclerosis. Curr Atheroscler Rep. [6]
[7] Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. [7]
[8] Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. [8]
[9] 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. [9]
[10] Sniderman AD et al. Familial combined hyperlipidemia: a clinically useful concept? Curr Opin Lipidol. [10]
[11] Young SG et al. GPIHBP1 and lipoprotein lipase: partners in plasma triglyceride metabolism. Cell Metab. [11]
[12] Taskinen MR, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. [12]
[13] Targher G et al. Non-alcoholic fatty liver disease and risk of cardiovascular disease. J Hepatol. [13]

Fuentes

  1. https://academic.oup.com/eurheartj/article/41/1/111/5556353
  2. https://academic.oup.com/eurheartj/article/32/11/1345/491494
  3. https://www.jci.org/articles/view/30010
  4. https://link.springer.com/chapter/10.1007/978-3-319-48382-5_3
  5. https://link.springer.com/article/10.1007/s00125-005-0134-8
  6. https://link.springer.com/article/10.1007/s11883-017-0684-3
  7. https://www.sciencedirect.com/science/article/pii/S0140673614611543
  8. https://www.jlr.org/article/S0022-2275(20)32630-5/fulltext
  9. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625
  10. https://journals.lww.com/colipidology/Abstract/2002/12000/Familial_combined_hyperlipidemia__a_clinically.5.aspx
  11. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(11)00374-3
  12. https://www.sciencedirect.com/science/article/pii/S0021915014004295
  13. https://www.journal-of-hepatology.eu/article/S0168-8278(09)00430-6/fulltext

Respuesta generada por inteligencia artificial a partir de las fuentes citadas. Verifica las fuentes antes de aplicarla.

¿Tienes una pregunta sobre tu propio caso? Itaca responde con fuentes en segundos.

Hacer una pregunta

Más preguntas sobre dislipidemias